Gilead Sciences (GILD) Stock Sees Positive Outlook Amid HIV, Liver, and Cancer Drug Momentum

Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the most undervalued NASDAQ stocks to buy now. Citing momentum in Gilead Sciences, Inc. (NASDAQ:GILD)’s product pipeline, Moody’s updated the company’s outlook from stable to positive on September 18, maintaining the company’s A3 senior unsecured ratings. The forecast takes into account Gilead’s recent clearance by regulators and introduction of Yeztugo, the first HIV prevention twice-yearly subcutaneous injectable.

According to Moody’s, Gilead’s liver and cancer platforms have a solid position for future expansion, especially with drugs like Livdelzi and Trodelvy.

Moreover, the firm identified governance risk concerns as a major factor in the rating update, indicating a favorable assessment of management’s financial strategy and credibility. In recent years, Gilead Sciences, Inc. (NASDAQ:GILD) has upheld conservative financial practices, concentrating on bolt-on acquisitions under $5 billion.

Gilead Sciences, Inc. (NASDAQ:GILD), a U.S. biopharmaceutical company headquartered in Foster City, California, focuses on developing antiviral treatments for illnesses such as COVID-19, hepatitis B and C, influenza, and HIV/AIDS.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.